Abstract
Objective: We present an interesting case of accidental overdose of latanoprost eye drops.
Case Report: A 71-year-old patient underwent an uncomplicated cataract surgery in his right eye. During the first postsurgical week he mistakenly used latanoprost eye drops six times daily instead of the prescribed tobramycin/dexamethasone eye drops. The patient experienced gradually decreasing visual acuity and was diagnosed with cystoid macular edema seven weeks after surgery. The cystoid macular edema resolved 4 weeks later after treatment with nepafenac 0.3% eye drops and oral acetazolamide. The cystoid macular edema recurred 2 weeks after rechallenge with latanoprost. The rechallenge-induced cystoid macular edema once again resolved after cessation of latanoprost and retreatment with nepafenac eye drops. A Naranjo assessment score of 7 was obtained, indicating a probable relationship between the patient’s symptoms and the suspect drug.
Keywords: Cystoid macular edema, uneventful phacoemulsification, latanoprost overdose, rechallenge, prostaglandin analogues, best corrected visual acuity, optical coherence tomography.
Graphical Abstract
Current Drug Safety
Title:Cystoid Macular Edema Due to Accidental Latanoprost Overdose After Uncomplicated Phacoemulsification
Volume: 13 Issue: 3
Author(s): Olga E. Makri, Iasonas K. Tsekouras, Panagiotis Plotas, Foteini Tsapardoni, Athina Pallikari and Constantine D. Georgakopoulos*
Affiliation:
- Department of Ophthalmology, Medical School, University of Patras, Patras,Greece
Keywords: Cystoid macular edema, uneventful phacoemulsification, latanoprost overdose, rechallenge, prostaglandin analogues, best corrected visual acuity, optical coherence tomography.
Abstract: Objective: We present an interesting case of accidental overdose of latanoprost eye drops.
Case Report: A 71-year-old patient underwent an uncomplicated cataract surgery in his right eye. During the first postsurgical week he mistakenly used latanoprost eye drops six times daily instead of the prescribed tobramycin/dexamethasone eye drops. The patient experienced gradually decreasing visual acuity and was diagnosed with cystoid macular edema seven weeks after surgery. The cystoid macular edema resolved 4 weeks later after treatment with nepafenac 0.3% eye drops and oral acetazolamide. The cystoid macular edema recurred 2 weeks after rechallenge with latanoprost. The rechallenge-induced cystoid macular edema once again resolved after cessation of latanoprost and retreatment with nepafenac eye drops. A Naranjo assessment score of 7 was obtained, indicating a probable relationship between the patient’s symptoms and the suspect drug.
Export Options
About this article
Cite this article as:
Makri E. Olga , Tsekouras K. Iasonas , Plotas Panagiotis , Tsapardoni Foteini , Pallikari Athina and Georgakopoulos D. Constantine *, Cystoid Macular Edema Due to Accidental Latanoprost Overdose After Uncomplicated Phacoemulsification, Current Drug Safety 2018; 13 (3) . https://dx.doi.org/10.2174/1574886313666180619163845
DOI https://dx.doi.org/10.2174/1574886313666180619163845 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Tuftsin – Properties and Analogs
Current Medicinal Chemistry Immobilization-Induced Behavioral Deficits are Attenuated But Coping with Repeated Stress Impaired in Apomorphine Injected Rats
Current Psychopharmacology Cytokines in the Central Nervous System: Targets for Therapeutic Intervention
Current Drug Targets - CNS & Neurological Disorders Atorvastatin Inhibited ROS Generation and Increased IL-1β And IL-6 Release by Mononuclear Cells from Diabetic Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Non-Canonical Peptides Bound to MHC
Current Pharmaceutical Design A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimers Disease
Current Drug Targets Emerging Influenza Viruses: Past and Present
Current Molecular Medicine The Updated Role of Oxidative Stress in Subarachnoid Hemorrhage
Current Drug Delivery Salusins in Hypertension and Related Cardiovascular Diseases
Current Drug Metabolism Group IIA Secretory PLA2 Inhibition by Ursolic Acid: A Potent Anti-Inflammatory Molecule
Current Topics in Medicinal Chemistry Potential Roles for G-Quadruplexes in Mitochondria
Current Medicinal Chemistry Induction of Serine Racemase Expression and D-Serine Release from Microglia by Secreted Amyloid Precursor Protein (sAPP)
Current Alzheimer Research Structural Heterogeneity and Multifunctionality of Lactoferrin
Current Protein & Peptide Science Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Current Drug Targets Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Age-Related Inflammation: the Contribution of Different Organs, Tissues and Systems. How to Face it for Therapeutic Approaches
Current Pharmaceutical Design Randomized Double-blind Placebo-controlled Trial of Celecoxib for the Prevention of Skin Toxicity in Patients Receiving Radiation Therapy for Breast Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Virulence Determinants of Equine Infectious Anemia Virus
Current HIV Research Conformations and Biological Activities of Amyloid Beta Peptide 25-35
Current Protein & Peptide Science